SABSW · As filed with the SEC
SAB Biotherapeutics balance sheet, by quarter
The statement as SAB Biotherapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Balance Sheets (Unaudited) · USD
| USD | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 |
|---|---|---|---|---|
| Current assets | ||||
| Cash and cash equivalents | 8,267,000 | 20,519,724 | 10,502,680 | 29,424,708 |
| Short-term investments | 94,365,000 | 86,871,857 | 86,089,779 | 81,455,925 |
| Accrued interest receivable | 1,844,000 | 1,555,061 | 946,781 | 559,954 |
| Prepaid expenses and other current assets | 3,461,000 | 3,835,400 | 3,513,384 | 1,836,160 |
| Total current assets | 107,937,000 | 112,782,042 | 101,052,624 | 113,276,747 |
| Deferred issuance cost | 0 | 0 | 150,145 | 0 |
| Long-term prepaid assets | 5,344,000 | 5,279,709 | 5,309,345 | 124,073 |
| Long-term investments | 105,346,000 | 110,235,540 | 46,892,882 | 50,608,587 |
| Operating lease right-of-use assets | 1,901,000 | 2,885,331 | 2,603,059 | 2,806,904 |
| Financing lease right-of-use assets | 3,453,000 | 3,474,306 | 3,496,012 | 3,517,718 |
| Property, plant and equipment, net | 14,229,000 | 13,813,570 | 13,305,902 | 13,114,339 |
| Total assets | 238,210,000 | 248,470,498 | 172,809,969 | 183,448,368 |
| Current liabilities | ||||
| Notes payable | — | — | 0 | 0 |
| Accounts payable | 3,855,000 | 3,544,958 | 3,145,805 | 2,954,985 |
| Accrued expenses and other current liabilities | 7,209,000 | 5,386,530 | 6,583,996 | 6,850,015 |
| Operating lease liabilities, current portion | 481,000 | 763,705 | 797,402 | 837,286 |
| Finance lease liabilities, current portion | 160,000 | 156,958 | 153,967 | 151,033 |
| Total current liabilities | 11,705,000 | 9,852,151 | 10,681,170 | 10,793,319 |
| Operating lease liabilities, noncurrent | 1,451,000 | 2,170,887 | 1,877,360 | 2,037,461 |
| Finance lease liabilities, noncurrent | 3,040,000 | 3,081,573 | 3,121,952 | 3,161,562 |
| Warrant liabilities | 7,229,000 | 6,117,586 | 5,635,112 | 2,381,677 |
| Total liabilities | 23,425,000 | 21,222,197 | 21,315,594 | 18,374,019 |
| Stockholders equity | ||||
| Series A Preferred Stock | 0 | 3 | 3 | 3 |
| Preferred Series B | 0 | 59 | 64 | 64 |
| Common stock; $0.0001 par value; 800,000,000 shares authorized at June 30, 2026 and December 31, 2025; 83,547,733 and 47,664,564 shares issued at June 30, 2026 and December 31, 2025, respectively, and 83,493,068 and 47,609,899 outstanding at June 30, 2026 and December 31, 2025, respectively | 8,000 | 7,580 | 4,766 | 4,756 |
| Treasury stock, at cost; 54,665 shares held at June 30, 2026 and December 31, 2025, respectively | (5,521,000) | (5,521,246) | (5,521,246) | (5,521,246) |
| Additional paid-in capital | 373,483,000 | 362,748,721 | 267,719,445 | 264,553,973 |
| Accumulated other comprehensive income (loss) | (930,000) | (222,764) | 186,510 | 71,223 |
| Accumulated deficit | (152,255,000) | (129,764,052) | (110,895,167) | (94,034,424) |
| Total stockholders' equity | 214,785,000 | 227,248,301 | 151,494,375 | 165,074,349 |
| Total liabilities and stockholders' equity | 238,210,000 | 248,470,498 | 172,809,969 | 183,448,368 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.